Mode
Home
Conditions Medications Drug Pipeline Weekly Digests
Text Size
Log in / Sign up
Home › Medications › quizartinib

quizartinib

2 published articles · Updated continuously

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
FDA Approves Vanflyta (quizartinib) for Newly Diagnosed FLT3-ITD-Positive AML in Adults
Oncology FDA Approval
FDA Approves Vanflyta (quizartinib) for Newly Diagnosed FLT3-ITD-Positive AML in Adults FDA approves new drug called Vanflyta for a specific type of blood cancer in adults.
Vanflyta is approved in combination with induction and consolidation chemotherapy, and as maintenance monotherapy, for adult patients with n…
FDA approves Vanflyta to treat acute myeloid leukemia in adults with a specific genetic change that makes the cancer harder to manage.
FDA Apr 16, 2026
Phase II trial compares quizartinib vs placebo with chemotherapy in FLT3 wild-type AML
Hematology Phase II
Phase II trial compares quizartinib vs placebo with chemotherapy in FLT3 wild-type AML Can adding quizartinib to standard chemo help adults with a common type of acute myeloid leukemia?
A randomized phase II trial compared standard chemotherapy plus quizartinib versus standard chemotherapy plus placebo in 273 adults with new…
Adding quizartinib to standard chemotherapy for newly diagnosed acute myeloid leukemia aims to help patients live longer without their cance…
CT.gov Mar 30, 2026